What is Haemonetics's EV / sales?

Haemonetics (HAE) reported EV / sales of 2.7× in Q1 2026.

How has Haemonetics's EV / sales changed year-over-year?

Haemonetics's EV / sales decreased by 10.7% year-over-year, from 3.1× to 2.7×.

What is the long-term trend for Haemonetics's EV / sales?

Over 5 years (2021 to 2026), Haemonetics's EV / sales has grown at a -17.6% compound annual growth rate (CAGR), from 7.2× to 2.7×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

Haemonetics HAE EV / sales

EV / sales at other companies

AbbottABT

4.6×-1.0×

TFX

TeleflexTFX

3.6×-1.0×

Boston ScientificBSX

7×-1.5×

MedtronicMDT

3.6×-0.4×

LivaNovaLIVN

2.3×+0.7×

ICU MedicalICUI

2×0.0×

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Calculated from Haemonetics’s reported figures.

enterprise value/total revenue=2.7×

Based on the most recent quarter.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's EV / sales?: Haemonetics (HAE) reported EV / sales of 2.7× in Q1 2026.
How has Haemonetics's EV / sales changed year-over-year?: Haemonetics's EV / sales decreased by 10.7% year-over-year, from 3.1× to 2.7×.
What is the long-term trend for Haemonetics's EV / sales?: Over 5 years (2021 to 2026), Haemonetics's EV / sales has grown at a -17.6% compound annual growth rate (CAGR), from 7.2× to 2.7×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.